Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4140930 | 0.84 | HSD11B1 (0.42) | ALDH1A1BPTFHSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL17746546 | 0.79 | ALDH1A1 (0.35) | ALDH1A1GAASMN1; SMN2P2RX7KMT2A | |
| SCHEMBL7258941 | 0.74 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL6860976 | 0.72 | GAA (0.38) | ALDH1A1HSD11B1GAAHSD17B10TSHR | |
| SCHEMBL11702345 | 0.71 | HSD11B1 (0.37) | HSD11B1KMT2A | |
| SCHEMBL1074062 | 0.69 | ALDH1A1 (0.57) | ALDH1A1BPTFHSD11B1SMN1; SMN2P2RX7 | |
| SCHEMBL25909650 | 0.69 | ALDH1A1 (0.57) | ALDH1A1BPTFHSD11B1SMN1; SMN2P2RX7 | |
| SCHEMBL5248488 | 0.68 | THRB (0.36) | ALDH1A1HSD11B1GAA | |
| SCHEMBL11676268 | 0.68 | EPHX2 (0.34) | ALDH1A1HSD11B1KMT2A | |
| SCHEMBL6854374 | 0.67 | EPHX1 (0.34) | ALDH1A1HSD11B1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-7402596-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1865774-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2006102588-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197565-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | ALDH1A1 3640/4885BPTF 2605/4885HSD11B1 3494/4885 |
| US-20090170838-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | ALDH1A1 3640/4885BPTF 2605/4885HSD11B1 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.